Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004221 | 0.85 | — | — | |
| SCHEMBL2129310 | 0.75 | — | — | |
| SCHEMBL18676255 | 0.75 | — | — | |
| SCHEMBL2129308 | 0.75 | — | — | |
| SCHEMBL270803 | 0.73 | CA12 (0.38) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL4510359 | 0.71 | — | — | |
| SCHEMBL269711 | 0.71 | CA12 (0.35) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL10305773 | 0.71 | CYP1A2 (0.31) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL4941316 | 0.71 | CYP1A2 (0.31) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL4941314 | 0.71 | CYP1A2 (0.31) | CA12CA1CA2CA9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2555747-A2 | A COMBINATION OF CROSSLINKED CATIONIC POLYMER AND AMPHOLYTIC POLYMER FOR PERSONAL AND HOUSEHOLD APPLICATIONS | Lubrizol Advanced Materials, Inc. (US) | 2013-02-13 | — | — | EP | claimed |
| WO-2011127364-A2 | A COMBINATION OF CROSSLINKED CATIONIC AND AMPHOLYTIC POLYMERS FOR PERSONAL AND HOUSEHOLD APPLICATIONS | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2011-10-13 | — | — | WO | claimed |
| EP-1647555-B1 | THE C-GLYCOSYLISOFLAVONES HAVING ALKYLAMINOALKOXYL SUBSTITUENT, THE PREPARATION AND THE USE OF THE SAME | INST RADIATION MED AMMS PLA (CN) | 2011-04-20 | — | — | EP | claimed |
| US-7727965-B2 | C-glycosylisoflavones having alkylaminoalkoxyl substituent, preparation and use of the same | HAINAN YANGPU NEW & SPECIAL MEDICINE CO., LTD. (CN) | 2010-06-01 | — | — | US | claimed |
| US-20080293642-A1 | C-Glycosylisoflavones Having Alkylaminoalkoxyl Substituent, Preparation and Use of the Same | INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) | 2008-11-27 | — | — | US | claimed |
| EP-1417190-B1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-10-22 | — | — | EP | claimed |
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | claimed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | claimed |
| US-7115607-B2 | Substituted piperazinyl amides and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | claimed |
| EP-1647555-A1 | THE C-GLYCOSYLISOFLAVONES HAVING ALKYLAMINOALKOXYL SUBSTITUENT, THE PREPARATION AND THE USE OF THE SAME | Institute of Radiation Medicine Academy of Military Medical Sciences of the Pla (CN) | 2006-04-19 | — | — | EP | claimed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | claimed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | claimed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | claimed |
| WO-2024014399-A1 | METHOD FOR PRODUCING FLUORINE-CONTAINING COPOLYMER | ＡＧＣ株式会社 | 2024-01-18 | — | — | WO | disclosed |
| WO-2024014400-A1 | METHOD FOR PRODUCING FLUORINE-CONTAINING COPOLYMER | ＡＧＣ株式会社 | 2024-01-18 | — | — | WO | disclosed |
| EP-3864002-B1 | ADDITION-FRAGMENTATION AGENT WITH PENDENT AMINE GROUPS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-12-27 | — | — | EP | disclosed |
| US-6069216-A | COPOLYMER HAVING EXCELLENT THIXOTROPY, EXHIBITING HIGH ADSORBABILITY TO SKIN AND HAIR; WHEN INCORPORATED AS THICKENER IN COSMETICS, MANIFESTS VERY SATISFACTORY TACTILE SENSATION | KAO CORPORATION (JP) | 2000-05-30 | — | — | US | disclosed |
| EP-0884334-A2 | Cationic group-containing copolymer and thickener | Kao Corporation (JP) | 1998-12-16 | — | — | EP | disclosed |
| EP-0697407-B1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS (JP) | 1997-06-25 | — | — | EP | disclosed |
| EP-0697407-A1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220324-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | CA12 3977/4885CA1 4542/4885CA2 3148/4885 |
| US-20080293642-A1 | C-Glycosylisoflavones Having Alkylaminoalkoxyl Substituent, Preparation and Use of the Same | UGCG, PIGO, GPI | CA12 492/4885CA1 584/4885CA2 367/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | CA12 3977/4885CA1 4542/4885CA2 3148/4885 |
| US-20040006067-A1 | Substituted piperidines and methods of use | MC4R, MC5R, MC1R | CA12 4764/4885CA1 4656/4885CA2 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.